<i>ESR1</i> predicts response to tamoxifen on YTMA 130 Subset.

<p>Kaplan-Meier curves all show 10-year recurrence-free survival. (A) Cases from the YTMA 130 Subset were split by the median <i>ESR1</i> AQUA score and shows no prognostic value. (B) <i>ESR1</i> high (AQUA >4.13) cases from the YTMA 130 Subset were split by tamoxifen treatment status. <i>ESR1</i> high patients who received tamoxifen had a statistically significant reduced risk of recurrence. (C) <i>ESR1</i> low (AQUA <4.13) cases from the YTMA 130 Subset were split by tamoxifen treatment status and show no statistically significant trend. (D) ER positivity on YTMA 130 determined by QIF with SP1 is prognostic. (E) ER positive cases from YTMA 130 were split by tamoxifen treatment status. Patients who received tamoxifen had a reduced risk of recurrence trending towards significance. All p values were calculated using the log-rank test.